Prof. Huiqing Yu 余慧青
Chief Physician, Professor
Department of Geriatric Oncology, Chongqing University Cancer Hospital, Chongqing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for lung, colorectal, gastric, liver, and soft tissue cancers. Focuses on chemotherapy, molecular targeted therapy, immunotherapy, cancer pain management, and nutritional support.
Dr. Yu is a Chief Physician, Professor, and Master’s Supervisor with over 30 years of experience. Serves as Administrative Director of the Geriatric Oncology Department and Clinical Nutrition Department, and Deputy Director of the Oncology Teaching Office. Specializes in comprehensive medical treatment, including standardized and personalized therapies for cancer pain and nutrition.
Professional roles
- Vice Chair, Chongqing Branch, Chinese Medical Association
- Vice Chair, Palliative Care Committee, China Anti-Cancer Association
- Standing Committee Member, Cancer Rehabilitation and Palliative Care Committee, China Anti-Cancer Association
- Chair, Cancer Rehabilitation and Palliative Care Committee, Chongqing Medical Biotechnology Society
Name order: in Chinese the family name comes first (Yu Huiqing). Papers usually list the name as Huiqing Yu or Yu H.
Selected publications
26 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Sci Rep, 2026 (senior author): Holistic oncologic management improves quality of life in driver gene negative advanced NSCLC a latent growth curve modeling study. PubMed 42437787
- Front Med (Lausanne), 2026 (senior author): Subcutaneous patient-controlled analgesia with hydromorphone for the treatment of refractory cancer pain in older hospitalized patients: a retrospective real-world study. PubMed 42344504
- Front Immunol, 2026 (senior author): JK5G postbiotics modulate gut microbiota and metabolome to alleviate cancer-related pain: a randomized controlled trial with multi-omics integration. PubMed 41859075
- Front Oncol, 2021 (first author): Knockdown of SNORA47 Inhibits the Tumorigenesis of NSCLC via Mediation of PI3K/Akt Signaling Pathway. PubMed 33816250
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion